Approved Bispecifics for the Treatment of Relapsed/Refractory Multiple Myeloma (R/R MM)
Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available.
EP: 1.Approved Bispecifics for the Treatment of Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 2.Administering Bispecifics to Patients with R/R MM
EP: 3.Administering Teclistamab for R/R MM in an Outpatient Setting
EP: 4.Monitoring Patients With R/R MM for CRS and ICANS
EP: 5.Outpatient Management of Teclistamab for R/R MM
EP: 6.Advice for Clinicians Administering Bispecifics to Patients With R/R MM
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
